BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY) After FDA Says Tirzepatide is No Longer on Shortage Lists
Tweet Send to a Friend
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $1,101.00 price target on Eli Lilly (NYSE: LLY).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
